SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jeffbas who wrote (3174)6/3/1999 10:25:00 AM
From: Vector1  Read Replies (3) of 10280
 
Jeff,
I agree that a public fight with the FDA is not a winning strategy. However, virtually every pharma does battle with the FDA behind closed doors. The lobbying that goes into getting agreement on the label is very intense and there is tremendous presure from sales and marketing to push the envelope on marketing materials. Xeno is their first marketed drug and they must show differentiation to take market share from the generics. SEPR has a very aggressive maybe even arogant management style. They were incredibly bold to grab the single isomer opportunity. Some of that same agressiveness that served them well in the past could be hurting them here.
Although you couldn't tell from todays stock movement. I for one am not complaining.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News